

# Olga D Ostroumova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2775840/publications.pdf>

Version: 2024-02-01

119  
papers

746  
citations

1170033

9  
h-index

651938

25  
g-index

194  
all docs

194  
docs citations

194  
times ranked

410  
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-Induced Atrial Fibrillation / Atrial Flutter. Rational Pharmacotherapy in Cardiology, 2022, 17, 1-18.	0.3	0
2	Thiazide and thiazide-like diuretics: how to make the right choice?. Kardiologiya, 2022, 62, 89-97.	0.3	0
3	Heart failure as a risk factor of adverse drug reactions. Part 1: potential changes in pharmacokinetics. Kachestvennaya Klinicheskaya Praktika, 2022, , 53-59.	0.2	0
4	Heart failure as a risk factor of adverse drug reactions. Part 2: potential changes in pharmacokinetics of some drugs. Kachestvennaya Klinicheskaya Praktika, 2022, , 60-74.	0.2	0
5	MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. Drug Metabolism and Personalized Therapy, 2022, 37, 41-46.	0.3	2
6	Genetic Risk Factors for Adverse Drug Reactions. Safety and Risk of Pharmacotherapy, 2022, 10, 48-64.	0.1	3
7	Prospects for using a perindopril/amlodipine combination in patients with hypertension and/or coronary artery disease and COVID-19: focus on the endothelium. Russian Journal of Cardiology, 2022, 27, 4888.	0.4	0
8	Drug-induced orthostatic hypotension. Medical Alphabet, 2022, , 14-22.	0.0	0
9	Drug-induced tremor. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 4-10.	0.2	0
10	Drug-induced hypertension. Medical Alphabet, 2022, , 8-13.	0.0	1
11	Drug-induced pulmonary artery hypertension. Kachestvennaya Klinicheskaya Praktika, 2022, , 53-63.	0.2	1
12	The problem of choice: original drug or generic? Emphasis on rosuvastatin. Rational Pharmacotherapy in Cardiology, 2022, 18, 225-230.	0.3	0
13	Anticoagulant therapy as a part of secondary stroke prevention in patients with atrial fibrillation. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 94-100.	0.2	2
14	Pulse pressure and cognitive impairment. Russian Journal of Cardiology, 2021, 26, 4317.	0.4	4
15	INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES". Obesity and Metabolism, 2021, 18, 5-99.	0.4	49
16	Expert consensus. Effect of antihypertensive therapy on cognitive functions. Systemic Hypertension, 2021, 18, 5-12.	0.1	4
17	Advanced Age as a Risk Factor of Drug-Induced Diseases. Safety and Risk of Pharmacotherapy, 2021, 9, 15-24.	0.1	4
18	Aspects of efficacy, safety and adherence to antihypertensive therapy with single pill combinations of valsartan, amlodipine and hydrochlorothiazide (Vamloset® and Co-Vamloset) in patients with 2 and 3 grade of arterial hypertension in the Russian clinical study VICTORY II. Systemic Hypertension, 2021, 18, 50-62.	0.1	0

#	ARTICLE	IF	CITATIONS
19	Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, 1, 4-52.	0.1	63
20	Optimization of Pharmacotherapy Within the Framework of a Patient-oriented Approach in the Treatment of Hypertension in Multimorbidity Patients (Clinical Case and Literature Review). Rational Pharmacotherapy in Cardiology, 2021, 17, 124-132.	0.3	0
21	Pharmacogenetics as a Way for Personalizing Diuretic Therapy: Focus on Torasemide. Rational Pharmacotherapy in Cardiology, 2021, 17, 119-123.	0.3	1
22	Antibiotic-associated drug-induced liver damage with cholestasis: actualization of problem in COVID-19 era. Medical Alphabet, 2021, , 31-43.	0.0	3
23	Possibilities of using fosinopril in treatment of patients with chronic kidney disease in combination with cardiovascular diseases and diabetes mellitus. Medical Alphabet, 2021, , 17-25.	0.0	0
24	Stroke and COVID-19. Medical Alphabet, 2021, , 26-30.	0.0	2
25	Inflammaging: inflammation and oxidative stress as a cause of aging and cognitive decline. Meditsinskiy Sovet, 2021, , 48-58.	0.1	2
26	Aspects of practical application of "STOPP/START" criteria in elderly patients with atrial fibrillation and chronic kidney disease in therapeutic department of multi-speciality hospital. Medical Alphabet, 2021, , 57-65.	0.0	2
27	Drug-induced hemolytic anemia. Medical Alphabet, 2021, , 49-56.	0.0	1
28	Modern view on chronic heart failure therapy: guidelines-2020 key messages and adjuvant therapy. Medical Alphabet, 2021, , 8-16.	0.0	0
29	Antithrombotic therapy in multimorbid patients with atrial fibrillation from standpoint of clinical recommendations of Ministry of Health of Russian Federation (2020). Effectiveness and safety of apixaban in patients with atrial fibrillation and concomitant diseases. Medical Alphabet, 2021, 1, 12-19.	0.0	0
30	Some groups of drugs which use is associated with development of drug-induced atrial fibrillation. Medical Alphabet, 2021, 1, 20-28.	0.0	1
31	Female Gender as a Risk Factor for the Development of Drug-Induced Diseases. Safety and Risk of Pharmacotherapy, 2021, 9, 85-94.	0.1	1
32	MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. Drug Metabolism and Personalized Therapy, 2021, .	0.3	0
33	Combined lipid-lowering therapy from standpoint of modern guidelines for management of dyslipidaemias. Medical Alphabet, 2021, , 13-19.	0.0	1
34	Antineoplastic agents associated with the development of drug-induced pancreatitis. Meditsinskiy Sovet, 2021, , 114-121.	0.1	0
35	Alcohol as a risk factor for drug-induced diseases. Kachestvennaya Klinicheskaya Praktika, 2021, , 52-66.	0.2	0
36	Drug-induced pancreatitis: focus on drugs used to treat cardiovascular disease. Medical Alphabet, 2021, , 37-42.	0.0	0

#	ARTICLE	IF	CITATIONS
37	Drugs associated with drug-induced interstitial lung diseases. Kachestvennaya Klinicheskaya Praktika, 2021, , 39-51.	0.2	0
38	Drug-induced ischemic stroke. Meditsinskiy Sovet, 2021, , 42-49.	0.1	0
39	Choosing an antianginal therapy strategy in patients with stable coronary artery disease in real clinical practice: the advantages of trimetazidine. Meditsinskiy Sovet, 2021, , 25-32.	0.1	0
40	Trimethylamine oxide and its possible role in the development and progression of cardiovascular disease. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 3014.	0.4	1
41	NSAID-induced liver damage with cholestasis. Medical Alphabet, 2021, , 37-48.	0.0	0
42	Drugs associated with drug-induced hyponatremia. Focus on antihypertensive drugs and proton pump inhibitors. Medical Alphabet, 2021, 1, 40-46.	0.0	0
43	Drugs associated with drug-induced hyponatremia. Medical Alphabet, 2021, , 92-99.	0.0	0
44	Treatment of upper respiratory tract infections: the role of doxycycline. Medical Alphabet, 2021, , 29-36.	0.0	0
45	Potential drug interactions with garlic. Medical Alphabet, 2021, 1, 47-51.	0.0	0
46	Comorbidity of non-alcoholic fatty liver disease and cardiovascular disease: focus on ademetionine and ursodeoxycholic acid. Medical Alphabet, 2021, 1, 13-20.	0.0	1
47	Drug-induced hypophosphatemia. Medical Alphabet, 2021, , 79-91.	0.0	0
48	Drug-induced hypocalcemia. Meditsinskiy Sovet, 2021, , 164-175.	0.1	0
49	Drugs associated with drug-induced pancreatitis: focus on rarely discussed drugs. Medical Alphabet, 2021, 1, 33-39.	0.0	0
50	Drug-Induced Acute Kidney Injury. Safety and Risk of Pharmacotherapy, 2021, 9, 117-127.	0.1	1
51	Drugs associated with DIP. Meditsinskiy Sovet, 2021, , 109-118.	0.1	0
52	Interaction of drugs and coffee. Consilium Medicum, 2021, 23, 777-783.	0.1	0
53	Drug-induced diarrhea associated with antineoplastic drugs. HERALD of North-Western State Medical University Named After I I Mechnikov, 2021, 13, 5-18.	0.1	0
54	Hepatic impairment as a risk factor of adverse drug reactions. Consilium Medicum, 2021, 23, 939-948.	0.1	1

#	ARTICLE	IF	CITATIONS
55	Drug-induced parkinsonism. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2021, 13, 91-97.	0.2	1
56	Food-drug interaction as a risk factor of drug-induced diseases: epidemiology, risk factors, potential mechanisms of interaction. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021, , 31-38.	0.2	1
57	Drug-induced pleural diseases. <i>HERALD of North-Western State Medical University Named After I I Mechnikov</i> , 2021, 13, 5-14.	0.1	0
58	The Capabilities of Amlodipine/Lisinopril Single-Pill Combination in the Treatment of Newly Diagnosed Arterial Hypertension in a Middle-Aged Patient (Case Report). <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 16, 221-230.	0.3	0
59	Drug-induced drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. <i>Drug Metabolism and Personalized Therapy</i> , 2020, .	0.3	5
60	Modern antihypertensive therapy: the effectiveness of a unique Russian fixed-dose combination of ramipril and indapamide. <i>Russian Journal of Cardiology</i> , 2020, 25, 3782.	0.4	6
61	Arterial hypertension in adults. Clinical guidelines 2020. <i>Russian Journal of Cardiology</i> , 2020, 25, 3786.	0.4	309
62	Russian Medical Society for Arterial Hypertension Expert Consensus: Hypertension and COVID-19. <i>Systemic Hypertension</i> , 2020, 17, 35-41.	0.1	9
63	Optimization of pharmacotherapy in a polymorbid patient with a combination of chronic heart failure and chronic kidney disease. <i>Consilium Medicum</i> , 2020, 22, 38-43.	0.1	2
64	Drug-Induced Fatty Liver Disease. <i>Safety and Risk of Pharmacotherapy</i> , 2020, 8, 66-76.	0.1	5
65	Drug-Induced Neutropenia and Agranulocytosis. <i>Safety and Risk of Pharmacotherapy</i> , 2020, 8, 109-122.	0.1	7
66	Atrial Fibrillation Associated with Anticancer Drugs. <i>Safety and Risk of Pharmacotherapy</i> , 2020, 8, 178-190.	0.1	4
67	Antineoplastic drugs and drug-induced liver damage with cholestasis. <i>Medical Alphabet</i> , 2020, 1, 47-54.	0.0	4
68	Drug-induced liver damage with cholestasis. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 61-74.	0.2	3
69	Evidence base regarding target levels of arterial pressure in patients after a stroke: focus on a geriatric population. <i>Systemic Hypertension</i> , 2020, 17, 51-61.	0.1	0
70	Atrial fibrillation and cognitive impairment: prevalence and pathophysiological mechanisms for the relationship (Part 1). <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2020, 12, 105-110.	0.2	3
71	Drug-Induced Heart Failure (Part 2: Mechanisms of Development, Clinical Signs, Differential Diagnosis,) <i>Tj ETQq1 1 0,784314 rgBT /Over</i>	0.1	0
72	Analysis of drug prescription appropriateness according to the STOPP/START criteria of the elderly patients with type 2 diabetes mellitus in the endocrinology department of a multi-speciality hospital. <i>Russian Journal of Geriatric Medicine</i> , 2020, , 47-56.	0.3	2

#	ARTICLE	IF	CITATIONS
73	Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 542 Td (recomm Pharmacotherapy, 2020, 8, 23-35.	0.1	1
74	Hypoglycemia and the risk of cognitive impairment and dementia in elderly and senile patients with type 2 diabetes. Diabetes Mellitus, 2020, 23, 72-87.	0.5	2
75	Target levels of blood pressure in patients with arterial hypertension and coronary heart disease. Arterial Hypertension (Russian Federation), 2020, 26, 15-26.	0.1	2
76	The Possibilities of Single-Pill Combinations of Antihypertensive Drugs in Cerebroprotection: Focus on the Combination of Amlodipine with Ramipril. Rational Pharmacotherapy in Cardiology, 2020, 16, 487-497.	0.3	0
77	Arterial hypertension and cognitive impairment: multimodal approach for patient care and nicergoline use. Meditsinskiy Sovet, 2020, , 72-80.	0.1	1
78	Drug-induced liver injuries in practice of primary care physician (review of clinical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 Td (recomm	0.0	1
79	First results of Russian multicenter prospective clinical study VICTORY II: Vamloset® and Co-Vamloset effectiveness and safety in patients with stage 2 and 3 arterial hypertension. Systemic Hypertension, 2020, 17, 36-47.	0.1	1
80	Implementation of the organoprotective properties of fixed combinations of valsartan, amlodipine and hydrochlorothiazide (Vamloset® and Co-Vamloset) in patients with grade 2 and 3 hypertension in the Russian clinical study VICTORY II. Systemic Hypertension, 2020, 17, 59-70.	0.1	0
81	Up-to-date potential of antithrombotic therapy in patients with coronary artery disease and diabetes. Russian Journal of Cardiology, 2020, 25, 4077.	0.4	0
82	Prevalence of geriatric syndromes in persons over 65 years: the first results of the EVCALIPT study. Russian Journal of Cardiology, 2020, 25, 3985.	0.4	13
83	COVID-19: a patient with cardiovascular disease at high risk. Systemic Hypertension, 2020, 17, 76-83.	0.1	0
84	Drugâ€™drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. Drug Metabolism and Drug Interactions, 2020, 35, .	0.3	4
85	Hypertension and menopause. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 115-127.	0.4	2
86	The effect of anticholinergic medications on cognitive function of patients 80 years and older with essential hypertension. Arterial Hypertension (Russian Federation), 2019, 25, 246-257.	0.1	5
87	Drug-induced long QT interval: prevalence, risk factors, treatment and prevention. Consilium Medicum, 2019, 21, 62-67.	0.1	10
88	Drug-Induced Eosinophilia. Safety and Risk of Pharmacotherapy, 2019, 7, 176-189.	0.1	3
89	Hypoglycemias in elderly patients with type 2 diabetes mellitus: possible risks and ways to prevent them. Profilakticheskaya Meditsina, 2019, 22, 109.	0.2	0
90	Malnutrition in Elderly Patients as a Complication of a Drug Therapy: Clinical Pharmacologistâ€™s Point of View. Safety and Risk of Pharmacotherapy, 2019, 7, 23-30.	0.1	0

#	ARTICLE	IF	CITATIONS
91	Complications of Pharmacotherapy with New Oral Anticoagulants Caused by Inter-Drug Interactions: Focus on Gastrointestinal Bleeding. Safety and Risk of Pharmacotherapy, 2019, 7, 65-71.	0.1	1
92	The application of the STOPP/START criteria in the elderly patients with type 2 diabetes mellitus and essential hypertension at the endocrinology department of a multidisciplinary hospital. Arterial Hypertension (Russian Federation), 2019, 25, 214-224.	0.1	1
93	Anticoagulant Therapy as a Tool for the Prevention of Cognitive Impairment Associated with Atrial Fibrillation. Rational Pharmacotherapy in Cardiology, 2019, 15, 713-724.	0.3	3
94	Prevention of gastrointestinal bleeding in patients receiving oral anticoagulants: focus on proton pump inhibitors. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 128-137.	0.4	1
95	Safety of Cholinesterase Inhibitors and NMDA Receptors Antagonists for the Treatment of Patients with Dementia. Safety and Risk of Pharmacotherapy, 2019, 7, 190-199.	0.1	2
96	Modern concepts of orthostatic hypotension. Complex Issues of Cardiovascular Diseases, 2019, 8, 116-126.	0.3	1
97	Orthostatic Hypotension: Definition, Pathophysiology, Classification, Prognostic Aspects, Diagnostics and Treatment. Rational Pharmacotherapy in Cardiology, 2018, 14, 747-756.	0.3	6
98	Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs. Diabetes Mellitus, 2018, 21, 307-318.	0.5	17
99	Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology/European Society of Arterial Hypertension for the management of arterial hypertension. Russian Journal of Cardiology, 2018, , 131-142.	0.4	35
100	Cardiovascular risk in type 2 diabetes patients. Cardiovascular Therapy and Prevention (Russian) Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50 3	0.4	3
101	Atrial fibrillation as Risk Factor for Development of Cognitive Function Impairment and Dementia. Potential of Anticoagulant Therapy in Their Prevention. Kardiologiya, 2018, 17, 76-88.	0.3	8
102	Antihypertension drugs in prevention of cognition disorder and dementia: focus on calcium channel blockers and diuretics. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 79-91.	0.4	0
103	24â€¢Hour Arterial Pressure Variability: Prognostic Significance, Methods of Evaluation, Effect of Antihypertensive Therapy. Kardiologiya, 2017, 17, 62-72.	0.3	7
104	BURNOUT SYNDROME IN PATIENTS WITH WORKPLACE HYPERTENSION. Rational Pharmacotherapy in Cardiology, 2016, 12, 675-680.	0.3	4
105	The Concept of Psychological Syndrome Analysis (Vygotsky-Luria-Zeigarnik School) in the Study of Neurodynamic and Motivational Impact on Memory Efficiency in Elderly Patients with Essential Hypertension. International Journal of Psychophysiology, 2016, 108, 160.	0.5	0
106	EFFECTIVENESS OF FIXED COMBINATION OF RAMIPIL/AMLODIPINE IN THERAPY OF ARTERIAL HYPERTENSION, CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS. Meditsinskiy Sovet, 2016, , 16-23.	0.1	2
107	FIXED ANTIHYPERTENSIVE DRUGS COMBINATION SELECTION WITH THE AIM OF ORGANS PROTECTION. Russian Journal of Cardiology, 2015, , 127-133.	0.4	0
108	ALCOHOL AND ARTERIAL HYPERTENSION. Rational Pharmacotherapy in Cardiology, 2014, 10, 79-82.	0.3	2

#	ARTICLE	IF	CITATIONS
109	Emotion Regulation in Patients with Essential Hypertension: Subjective-evaluative, Physiological, and Behavioral Aspects. <i>Procedia, Social and Behavioral Sciences</i> , 2014, 127, 686-690.	0.5	2
110	Effect of citicoline on blood pressure variability. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2014, .	0.2	0
111	Personal Factors of Emotional Burnout in Patients with "Hypertension at Work": <i>Procedia, Social and Behavioral Sciences</i> , 2013, 86, 407-412.	0.5	4
112	Violations of Emotional Regulation in Patients with Stress-induced Hypertension. <i>Procedia, Social and Behavioral Sciences</i> , 2013, 78, 295-299.	0.5	2
113	FIXED COMBINATION OF THE CALCIUM CHANNEL BLOCKER LERCANIDIPINE AND ANGIOTENSIN CONVERTING ENZYME INHIBITOR ENALAPRIL: POSSIBILITY OF USAGE. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 177-182.	0.3	0
114	LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 79-85.	0.3	1
115	Psychophysiological mechanisms of mental stress reactions in patients with "hypertension at work" and patients with essential hypertension: a comparative analysis. <i>Psychology in Russia: State of the Art</i> , 2013, 6, 78.	0.1	2
116	Motivation as a factor affecting the efficiency of cognitive processes in elderly patients with hypertension. <i>Psychology in Russia: State of the Art</i> , 2013, 6, 186.	0.1	0
117	TREATMENT OF CHRONIC HEART FAILURE: FOCUS ON METOPROLOL SUCCINATE. <i>Rational Pharmacotherapy in Cardiology</i> , 2012, 8, 798-803.	0.3	0
118	NEW APPROACHES OF THE HYPERTENSION TREATMENT: FROM CHOOSING THE BEST DRUG TO CHOOSE THE OPTIMUM DRUGS COMBINATION. <i>Rational Pharmacotherapy in Cardiology</i> , 2010, 6, 709-716.	0.3	3
119	The psychological and hemodynamic features of patients with arterial hypertension under emotional stress. <i>Arterial Hypertension (Russian Federation)</i> , 2005, 11, 29-33.	0.1	3